Company / R&D Expense
CHINA PHARMA HOLDINGS, INC. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$280.9K
FY2025
5-year range
$185.9K / $378.0K
FY2021-FY2025
Trend
+17.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 10 years, ranging from $90,474 in FY2018 to $961,897 in FY2016.
Based on SEC 10-K filings.
$280,901 in FY2025 with a 5-year CAGR of +4.1%.
Improved from $240,080 to $280,901 over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +14.8%
- 5-Year CAGR
- +4.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +4.1%, indicating consistent growth.
- In FY2025, r&d expense increased 17.0% year-over-year.
- Peak r&d expense was recorded in FY2016.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $280.9K | +17.0% |
| FY2024 | $240.1K | +0.0% |
| FY2023 | $240.1K | +29.2% |
| FY2022 | $185.9K | -50.8% |
| FY2021 | $378.0K | +64.6% |
| FY2020 | $229.6K | +33.2% |
| FY2019 | $172.4K | +90.5% |
| FY2018 | $90.5K | -75.3% |
| FY2017 | $366.0K | -62.0% |
| FY2016 | $961.9K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026